Follow The Filings

NTRA Natera Inc.

Health Care, filed as NATERA INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 6 managers in 2026 Q2, sold by 3

  • 1 Owner
  • #85
  • Max 0.3%
  • Master 0.17%
  • $2.6M
  • 1 reduce

In 2026 Q3 Torray Investment Partners trimmed Natera.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 0.34%

Who owns NTRA

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.34%, was 0.36% Reduce −36.0% 6,225 $2.6M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NTRA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NTRA insider trades
  • None no insider bought on the open market
  • $49.4M sold by 4 insiders outside a trading plan
  • $282M sold by 10 insiders under 10b5-1 plans
  1. Michael Burkes Brophy CFO
    Planned sale
    $1.3M 3,084 shares at $425.90 6.2% of stake
    Traded Oct 28–30 Filed Oct 30
    ↗
  2. Jonathan Sheena Founder
    Planned sale
    $1.3M 3,150 shares at $410.55 1.4% of stake
    Traded Oct 21 Filed Oct 23
    ↗
  3. Jonathan Sheena Founder
    Planned sale
    $604K 1,500 shares at $402.47 15% of stake
    Traded Oct 16 Filed Oct 20
    ↗
  4. Matthew Rabinowitz Chair
    Planned sale
    $20.1M 50,000 shares at $402.64 2.3% of stake
    Traded Oct 15 Filed Oct 16
    ↗
  5. Solomon Moshkevich President, Clinicaldiagnostics
    Planned sale
    $1.2M 3,000 shares at $414.22 2.7% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  6. Steven Leonard Chapman CEO
    Planned sale
    $526K 1,273 shares at $413.31 1.3% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  7. Jonathan Sheena Founder
    Planned sale
    $7M 18,064 shares at $388.01 67% of stake
    Traded Sep 23 Filed Sep 25
    ↗
  8. Jonathan Sheena Founder
    Planned sale
    $3.2M 9,150 shares at $351.49 4% of stake
    Traded Sep 15–16 Filed Sep 17
    ↗
  9. Matthew Rabinowitz Chair
    Planned sale
    $34.8M 102,000 shares at $341.15
    Traded Sep 14–15 Filed Sep 16
    ↗
  10. Matthew Rabinowitz Chair
    Planned sale
    $16.4M 50,000 shares at $327.97 2.2% of stake
    Traded Sep 11 Filed Sep 11
    ↗
  11. Solomon Moshkevich President, Clinicaldiagnostics
    Planned sale
    $962K 3,000 shares at $320.73 2.3% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  12. Steven Leonard Chapman CEO
    Planned sale
    $545K 1,698 shares at $320.99 1.7% of stake
    Traded Sep 1 Filed Sep 3
    ↗
  13. Jonathan Sheena Founder
    Planned sale
    $2M 6,000 shares at $325.32 2.5% of stake
    Traded Aug 10 Filed Aug 14
    ↗
  14. Jonathan Sheena Founder
    Planned sale
    $2.9M 9,150 shares at $315.66 3.7% of stake
    Traded Aug 7 Filed Aug 7
    ↗
  15. Matthew Rabinowitz Chair
    Planned sale
    $642K 2,000 shares at $320.90 50% of stake
    Traded Aug 7 Filed Aug 7
    ↗

Also filed in the last 12 months, not counted as buying or selling: 98 sales to cover taxes, 63 stock grants, 25 option exercises, 5 gifts, and 1 share withholding for taxes.

Congress

1 member of Congress traded NTRA in the last three years: 3 buys and 1 sale. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Sep 22, 2025 filed Oct 15, 2025
  2. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Aug 22, 2025 filed Sep 5, 2025
  3. Josh Gottheimer D-NJ-5Joint Partial sale $1K–$15K Jul 22, 2025 filed Aug 11, 2025
  4. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Nov 20, 2024 filed Dec 5, 2024

SEC filings

Recent issuer filings from EDGAR, 3 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 39 minutes ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.08B $1.7B $2.31B
Net income -$434.8M -$190.43M -$208.16M
Net margin * -40.2% -11.2% -9.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.26B $1.38B $1.5B
Total non-current assets * $183.15M $284.92M $901.4M
Total assets $1.44B $1.66B $2.4B
Total current liabilities $307.27M $344.04M $441.23M
Total non-current liabilities * $369.1M $121.27M $244.7M
Total equity $0.765B $1.2B $1.71B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$246.96M $135.66M $215.3M
Cash from investing $168.5M $137.62M -$132.21M
Cash from financing $254.46M $30.2M $47.46M
Net change in cash * $176M $303.49M $130.55M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.